Cheng Hua

Jinghai He, Cheng Hua, Chunyang Zhou et al.

We develop a portfolio allocation framework that leverages deep learning techniques to address challenges arising from high-dimensional, non-stationary, and low-signal-to-noise market information. Our approach includes a dynamic embedding method that reduces the non-stationary, high-dimensional state space into a lower-dimensional representation. We design a reinforcement learning (RL) framework that integrates generative autoencoders and online meta-learning to dynamically embed market information, enabling the RL agent to focus on the most impactful parts of the state space for portfolio allocation decisions. Empirical analysis based on the top 500 U.S. stocks demonstrates that our framework outperforms common portfolio benchmarks and the predict-then-optimize (PTO) approach using machine learning, particularly during periods of market stress. Traditional factor models do not fully explain this superior performance. The framework's ability to time volatility reduces its market exposure during turbulent times. Ablation studies confirm the robustness of this performance across various reinforcement learning algorithms. Additionally, the embedding and meta-learning techniques effectively manage the complexities of high-dimensional, noisy, and non-stationary financial data, enhancing both portfolio performance and risk management.

Jinghai He, Cheng Hua, Yingfei Wang et al.

Drug discovery is a complex process that involves sequentially screening and examining a vast array of molecules to identify those with the target properties. This process, also referred to as sequential experimentation, faces challenges due to the vast search space, the rarity of target molecules, and constraints imposed by limited data and experimental budgets. To address these challenges, we introduce a human-in-the-loop framework for sequential experiments in drug discovery. This collaborative approach combines human expert knowledge with deep learning algorithms, enhancing the discovery of target molecules within a specified experimental budget. The proposed algorithm processes experimental data to recommend both promising molecules and those that could improve its performance to human experts. Human experts retain the final decision-making authority based on these recommendations and their domain expertise, including the ability to override algorithmic recommendations. We applied our method to drug discovery tasks using real-world data and found that it consistently outperforms all baseline methods, including those which rely solely on human or algorithmic input. This demonstrates the complementarity between human experts and the algorithm. Our results provide key insights into the levels of humans' domain knowledge, the importance of meta-knowledge, and effective work delegation strategies. Our findings suggest that such a framework can significantly accelerate the development of new vaccines and drugs by leveraging the best of both human and artificial intelligence.